April 20, 2021 -- Lineage Cell Therapeutics and Immunomic Therapeutics have signed a worldwide license and development collaboration agreement to generate a novel candidate derived from Lineage's VAC allogeneic cancer immunotherapy platform, which targets a proprietary, tumor-associated antigen construct provided by Immunomic for the treatment of glioblastoma multiforme.
The VAC platform is used to produce allogeneic, modified dendritic cells derived from pluripotent stem cells. The platform can be modified to carry selected antigens, including patient-specific tumor neo-antigens or viral antigens.
Lineage and Immunomic will collaborate on the manufacturing and clinical development of the novel VAC product candidate. Following development and delivery of current good manufacturing practice (cGMP) VAC product material, Immunomic will assume full and independent clinical and commercial responsibility for further advancement of the program.
Under the agreement, Lineage will be entitled to upfront payments totaling $2 million in the first year and up to $87 million in development and commercial milestones across multiple indications and territories. Lineage will also be eligible to receive royalties up to 10% on net sales of future products.
Copyright © 2021 scienceboard.net